Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Modus Therapeutics Holding AB is a life sciences company focused on developing innovative treatments for high-impact diseases. This Swedish firm primarily engages in the research and development of pharmaceutical products targeting severe and rare conditions, aimed at improving patient outcomes and quality of life. Modus Therapeutics is particularly known for its work in advancing therapies for sickle cell disease and other inflammatory conditions, reflecting its commitment to addressing unmet medical needs. These therapeutic products are designed to cater to a global market, given the universal challenges posed by the diseases the company targets. By fostering a pipeline of potential treatments, Modus Therapeutics plays a vital role in the biopharmaceutical sector, contributing to the broader healthcare ecosystem. Its efforts in drug development signify its importance in pushing forward medical advancements and offering hope to patients who suffer from chronic and debilitating illnesses.
kr 0.02
kr 0.00 (-0.93%)
Live · 10:45 PM · Twelve Data
ROIC dropped from -126.26% to -255.75%, capital efficiency is deteriorating. Negative free cash flow of -kr 18M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 0.00
Net Income (TTM)
-kr 19M
▼ -19.3% YoY
Op. Margin
—
ROIC
-255.75%
▼ -129.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 18M
▼ -23.1% YoY
Op. Cash Flow (TTM)
-kr 16M
▼ -23.1% YoY
Net Debt
-kr 11M
Net Cash Position
Cash & Equiv.
kr 11M
Continue Research
Modus Therapeutics Holding AB (MODTX.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Modus Therapeutics Holding AB scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Modus Therapeutics Holding AB scores 10 out of 100 on Intrinsiqq's quality score, passing 1 of 4 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a -255.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh MODTX.XSTO's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.